Sumitomo Chemical Company, Limited
Sumitomo Chemical | Discrepancies and Impact of Sumitomo Pharma Subsidiary’s Performance | May 2026
Sumitomo Pharma's FY2026 individual performance was ¥249,530 million in sales, ¥19,359 million in operating income, ¥62,940 million in ordinary income, and ¥114,981 million in net income, all significantly increased compared to the previous period. The differences are due to asset transfer and dividend recognition.
Key Figures
- Sales Revenue: ¥249,530 million (up 82.9% YoY)
- Operating Income: ¥19,359 million (up 66.8% YoY)
- Ordinary Income: ¥62,940 million (up 423.3% YoY)
AI要約
Performance Overview
Sumitomo Pharma's FY2026 individual performance recorded sales of ¥249,530 million, operating income of ¥19,359 million, ordinary income of ¥62,940 million, and net income of ¥114,981 million, all substantially increased from the previous period. The revenue growth was mainly due to sales recognition from the transfer of US core product patents and dividend income, with notable increases in both sales and ordinary income.
Background of Discrepancies and Future Impact
The main reasons for the differences are the recognition of sales through asset transfer by Sumitomo Pharma and the reflection of dividends received from SMPS Corporation. As a result, net income also exceeded the previous period. However, the impact on Sumitomo Chemical's consolidated performance is expected to be minimal, and no major changes are anticipated in future business strategies or performance forecasts.
Sumitomo Chemical Co., Ltd.
Company overview · Stock price · Financial data · All IR
